Compare Davita Inc (DVA) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs IONQ Inc — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while IONQ Inc trades at $39.55 (market cap $14.67B). The key difference: Davita Inc and IONQ Inc are close in size by market cap, and Davita Inc is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals.
| DVA | IONQ | |
|---|---|---|
Market Cap | $14.92B | $14.67B |
Sector | Health | Technology |
52-Week High | $235.71 | $82.09 |
52-Week Low | $103.87 | $26.59 |
Enterprise Value | $27.47B | $12.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
IONQ shares declined 9.29% to $38.88 amid broader quantum computing sector weakness, though technical indicators show oversold conditions with RSI at 16.05. The company maintains a mixed fundamental picture with strong revenue growth projections ($130M in 2025 to $187M in 2026) but significant operating losses. Analyst sentiment remains divided with a 50/50 buy/hold split despite a consensus price target of $73.75 representing 90% upside potential from current levels.
The stock presents high-risk, high-reward potential with Wall Street recognizing IONQ's leadership in trapped-ion quantum computing technology but concerned about cash burn and execution risks. Near-term catalysts include Q2 2026 earnings and the planned 256-qubit system demonstration, though the stock faces volatility from speculative trading and competitive pressures in the emerging quantum sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
